华东医药：2021年半年度报告（英文版）.PDF

《华东医药：2021年半年度报告（英文版）.PDF》由会员分享，可在线阅读，更多相关《华东医药：2021年半年度报告（英文版）.PDF（119页珍藏版）》请在淘文阁 - 分享文档赚钱的网站上搜索。

1、The Half Year Report 2021 of Huadong Medicine Co., Ltd 1 Huadong Medicine Co., Ltd. The Half Year Report 2021 August 2021 The Half Year Report 2021 of Huadong Medicine Co., Ltd 2 Section I. Important Declaration, Contents and Definitions The Board of Directors, Board of Supervisors, directors, super

2、visors and senior management of Huadong Medicine Co., Ltd. (hereinafter referred to as the “Company”) hereby guarantee that the information presented in this half year report is authentic, accurate and complete and free of any false records, misleading statements or material omissions, and shall und

3、ertake individual and joint legal liabilities. Lv Liang, the Companys legal representative and the officer in charge of accounting, and Qiu Renbo, head of accounting department (accounting supervisor) hereby declare and guarantee that the financial statements in this half year report are authentic,

4、accurate and complete. All directors have attended the Board of Directors meeting to review this half year report. The future plans, development strategies and other forward-looking statements in this half year report shall not be considered as substantial commitment of the Company to investor. Inve

5、stors and related parties should maintain sufficient risk awareness, and should understand the difference between plans, forecasts and promises. Investors are kindly reminded to pay attention to possible investment risks. The Company faced various risks in its operations, involving industry The Half

6、 Year Report 2021 of Huadong Medicine Co., Ltd 3 policies, markets, R&D of new drugs, product price reduction, etc. For details, refer to “X. Risks and Countermeasures” in “Section III. Discussion and Analysis of the Management”. We thank all investors for paying attention to the Companys operations

7、, and we hope that you can be aware of investment risks. The company does not plan to distribute cash dividends, no bonus share will be issued; and no capital reserve will be converted to increase the share capital. According to “Stock Listing Rules of the Shenzhen Stock Exchange”, if listed compani

8、es have both Chinese or other language version of public notice, they should ensure the content of both versions are the same. In the case of discrepancy, the original version in Chinese shall prevail. The Half Year Report 2021 of Huadong Medicine Co., Ltd 4 Contents Section I. Important Declaration

9、, Contents and Definitions . 2 Section II. Company Profile and Key Financial Indicators . 8 Section III. Discussion and Analysis of the Management. 11 Section IV. Corporate Governance . 45 Section V. Environmental and Social Responsibility . 46 Section VI. Important Matters . 59 Section VII. Share C

10、hange and Shareholders . 84 Section VIII. Preferred Shares . 89 Section IX. Information about Bonds . 90 Section X. Financial Report . 91 The Half Year Report 2021 of Huadong Medicine Co., Ltd 5 Documents Available for Reference I. Financial Statements carrying the signatures and stamps of the Compa

11、ny Principal, the Chief Financial Officer and the person in charge of accounting firm; II. Original copies of all documents and the announcements thereof disclosed in the reporting period on the designated newspaper. The Half Year Report 2021 of Huadong Medicine Co., Ltd 6 Definitions Term refers to

12、 Definition CSRC refers to China Securities Regulatory Commission SSE refers to Shenzhen Stock Exchange Huadong Medicine/the Company/our Company refers to Huadong Medicine Co., Ltd. CGE refers to China Grand Enterprises, Inc. Huadong Medicine Group refers to Hangzhou Huadong Medicine Group Co., Ltd.

13、 Zhongmei Huadong refers to Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Jiangdong Company refers to Hangzhou Zhongmei Huadong Pharmaceutical Jiangdong Co., Ltd. Jiuyang Bio refers to Jiangsu Jiuyang Biopharm Co., Ltd. Xian Bohua refers to Huadong Medicine (Xian) Bohua Pharmaceutical Co., Ltd.

14、 Jiuyuan Gene refers to Hangzhou Jiuyuan Gene Engineering Co., Ltd. Doer Biologics refers to Zhejiang Doer Biologics Corporation Huadong Ningbo Company refers to Huadong Ningbo Medicine Co., Ltd. Chongqing Peg-Bio refers to Chongqing Peg-Bio Biopharm Co., Ltd. Qyuns Therapeutics refers to Qyuns Ther

15、apeutics Co., Ltd. Nuoling Biomedical refers to Nuoling Biomedical Technology (Beijing) Co., Ltd. Yuanda Investment Management refers to Shanghai Yuanda Investment Management Co., Ltd. Fuguang Chengdu refers to Fuguang Chengdu Equity Investment Management Co., Ltd. Hangzhou High-Tech refers to Hangz

16、hou High-Tech Venture Capital Management Co., Ltd. Yuanda Huachuang refers to Beijing Yuanda Huachuang Investment Co., Ltd. Hangzhou Heda refers to Hangzhou Heda Industrial Fund Investment Co., Ltd. Pharmaceutical Industry Fund/Fuguang Hongxin refers to Hangzhou Fuguang Hongxin Equity Investment Par

17、tnership (L.P.) Sinclair refers to Sinclair Pharma Limited vTv Company refers to vTv Therapeutics LLC R2 refers to R2 Technologies,Inc. MediBeacon refers to MediBeacon Inc. ImmunoGen refers to ImmunoGen, Inc. Provention Bio refers to Provention Bio, Inc. RAPT refers to RAPT Therapeutics,Inc. The Hal

18、f Year Report 2021 of Huadong Medicine Co., Ltd 7 Kylane refers to Kylane Laboratoires SA High Tech refers to High Technology Products, S.L.U. LG refers to LG Chem Ltd Jetema refers to Jetema. Co,.ltd Exscientia refers to Exscientia Ltd. GMP refers to Good Manufacturing Practice CGMP refers to Curre

19、nt Good Manufacture Practices GSP refers to Good Supply Practice BE refers to Bioequivalence CDE refers to Center for Drug Evaluation (of National Medical Products Administration) MAH refers to Marketing Authorization Holder FDA refers to (U.S.) Food and Drug Administration NMPA refers to National M

20、edical Products Administration NDA refers to New Drug Application ANDA refers to Abbreviated New Drug Application ICH refers to International Council for Harmonisation (of Technical Requirements for Pharmaceuticals for Human Use) IND refers to Investigational New Drug PK/PD refers to pharmacokinetic

21、s/pharmacodynamics CMC refers to Chemistry, Manufacturing and Control CMO refers to Contract Manufacturing Organization CDMO refers to Contract Development and Manufacturing Organization PMA refers to Premarket Application QA refers to Quality Assurance (department) Catalogue of Drugs for Insurance（

22、2020） refers to Catalogue of Drugs for Basic National Medical Insurance/Employment Injury Insurance/Birth Insurance（2020） ADC refers to Antibody-Drug Conjugate EHS refers to Environment、Health、Safety Prescription Drugs refers to Drugs that can only be purchased and used according to prescriptions is

23、sued by physicians OTC refers to Over The Counter MRCT refers to International Multi-center Clinical Trial RWS/RWR refers to Real World Study/Real World Research The Half Year Report 2021 of Huadong Medicine Co., Ltd 8 Section II. Company Profile and Key Financial Indicators I. Company information S

24、tock name (abbreviation) Huadong Medicine Stock code 000963 Stock listed on Shenzhen Stock Exchange Company name in Chinese 华东医药股份有限公司 Company name in Chinese (abbreviation, if any) 华东医药 Company name in English (if any) HUADONG MEDICINE CO., LTD Company name in English (abbreviation, if any) HUADONG

25、 MEDICINE Legal representative Lv Liang II. Contact persons and contact information Secretary of the Board of Directors Securities Affairs Representative Name Chen Bo / Contact address 866 Moganshan Road, Hangzhou / Tel. 0571-89903300 / Fax 0571-89903300 / Email address / III. Other information 1. C

26、ompanys contact information Whether there is any change in the Companys registered address, office address, zip code, company website or company email address during the reporting period. Applicable N/A There is no change in the Companys registered address, office address, zip code, company website

27、or company email address during the reporting period. For details, please refer to 2020 Annual Report. 2. Information disclosure and place of the report Whether there is alteration in information disclosure and place of the report during the reporting period. Applicable N/A The Half Year Report 2021

28、 of Huadong Medicine Co., Ltd 9 The media selected by the Company for information disclosure, the website designated by CSRC for publication of the half year report, and the location of preparation of the Companys half year report have not changed during the reporting period. For details, please ref

29、er to the 2020 Annual Report. IV. Key accounting data and financial indicators Whether the Company needs to perform a retroactive adjustment or restatement of previous accounting data Yes No Current reporting period Same period last year Change of the current reporting period over the same period la

30、st year(%) Operating revenue (yuan) 17,179,437,902.61 16,660,934,157.64 3.11% Net profit attributable to shareholders of listed companies (yuan) 1,300,346,324.85 1,731,184,721.25 -24.89% Net profit attributable to shareholders of listed companies after deducting non-recurring gains/losses (yuan) 1,1

31、93,980,887.18 1,406,723,973.10 -15.12% Net cash flow from operating activities (yuan) 1,738,512,372.11 1,255,542,667.29 38.47% Basic earnings per share (yuan/share) 0.7431 0.9894 -24.89% Diluted earnings per share (yuan/share) 0.7431 0.9894 -24.89% Weighted average return on equity (ROE) 8.54% 13.12

32、% -4.58% End of the current reporting period End of last year Change of the end of the current reporting period over the end of last year(%) Total assets (yuan) 26,108,178,089.87 24,201,348,154.75 7.88% Net assets attributable to shareholders of listed companies (yuan) 15,567,274,148.76 14,619,821,3

33、08.60 6.48% Share capital of the Company as of the trading day before disclosure Share capital of the Company as of the trading day before disclosure (share) 1,749,809,548 Fully diluted earnings per share calculated on the basis of the latest Share capital Dividends paid on preferred shares 0.00 Per

34、petual bond interest paid (yuan) 0.00 Fully diluted earnings per share calculated on the basis of the latest Share capital (yuan/share) 0.7431 The Half Year Report 2021 of Huadong Medicine Co., Ltd 10 V. Differences in accounting data under domestic and overseas accounting standards 1. Differences i

35、n net profit and net assets disclosed in financial statements under international and Chinese accounting standards Applicable N/A There are no differences in net profit and net assets disclosed in financial statements under international and Chinese accounting standards. 2. Differences in net profit

36、 and net assets disclosed in financial statements under overseas and Chinese accounting standards Applicable N/A There are no differences in net profit and net assets disclosed in financial statements under overseas and Chinese accounting standards. VI. Items and amounts of non-recurring gains/losse

37、s Applicable N/A Unit: RMB yuan Item Amount Note Gains/losses on disposal of non-current assets (including the written-off part of the accrued assets impairment reserve) -110,119.08 Government grants included in current gains/losses (excluding those closely related to operating activities and measur

38、ed according to unified national standards) 138,308,095.20 Mainly due to the confirmation of government grants by subsidiaries in the current period. Receivables subject to separate impairment test and reversal of reserve for impairment of contract assets 5,388,185.00 Other non-operating revenue or

39、expenditure expect above-mentioned items -4,916,566.97 Minus: Amount affected by income tax 22,095,294.54 Amount affected by rights and interests of minority stakeholders (after tax) 10,208,861.94 Total 106,365,437.67 - If the Company recognizes an item as a non-recurring gain/loss based on the “Int

40、erpretative Announcement No. 1 on Information Disclosure Criteria for Public Companies Non-Recurring Profit/Loss” or recognizes an item satisfying the definition of non-recurring gain/loss in the announcement as a recurring gain/loss, reasons should be specified. Applicable N/A No such case during t

41、he reporting period. The Half Year Report 2021 of Huadong Medicine Co., Ltd 11 Section III. Discussion and Analysis of the Management I. Main business of the company during the reporting period 1. Main business of the company Huadong Medicine Co., Ltd. (stock code: 000963), founded in 1993 and headq

42、uartered in Hangzhou, Zhejiang Province, was listed on Shenzhen Stock Exchange in December 1999. After more than 20 years of development, its business covers the whole pharmaceutical industrial chain. With the pharmaceutical industry as its core, the Company expands its medicine business and aesthet

43、ic medicine industry. It has developed into a large comprehensive listed pharmaceutical company integrating R&D, production and sales of medicine. The pharmaceutical industry of the Company focuses on R&D, production and sales of specialist medication, chronic disease medication and medication for s

44、pecial purposes. The Company has formed core product pipelines in such fields as chronic kidney diseases, transplantation immunity, internal secretion and gastrointestinal system, and owns a number of first-line clinical medications with market advantages in China. Meanwhile, through independent dev

45、elopment, external introduction and project cooperation, the Company focuses on the R&D layout of innovative drugs and generic drugs with high technical barriers in the three core fields of anti-tumor, internal secretion and autoimmunity. The Company continues to carry out international product regi

46、stration, international certification, consistency evaluation, etc., and continues to achieve results, forming an international pharmaceutical industry system. The Company has four business segments, including Traditional Chinese Medicine (TCM) and Western Medicine, medical devices, ginseng, antler

47、and other herbs, and health industry, covering pharmaceutical wholesale, pharmaceutical retail, third-party pharmaceutical logistics characterized by cold chain, pharmaceutical e-commerce, hospital value-added service, and featured mega health industry, providing customers with integrated solutions.

48、 Committed to the R&D, production and sales of a series of advanced international aesthetic brands and high-end aesthetic medicine products, the Companys aesthetic medicine business targets the global high-end aesthetic medicine market and focuses on the R&D, production and sales of the latest produ

49、cts and devices in facial micro-plastic surgery and skin management. Sinclair, a wholly-owned subsidiary of the Company that is headquartered in the United Kingdom, has production bases in France and the Netherlands, and promotes and sells long-effect microsphere fillers for injection, hyaluronic ac

50、id, as well as face thread lift products in the global market. The Half Year Report 2021 of Huadong Medicine Co., Ltd 12 Sinclair is the global operation platform of the Company for aesthetic medicine business. The aesthetic medicine sector also includes High Tech (Spain), an overseas wholly-owned s